OncoTargets and Therapy

Aims and Scope

Editor-in-Chief: Professor Gaetano Romano

OncoTargets and Therapy is an Open Access, peer-reviewed journal covering molecular diagnosis and targeted molecular precision therapy for all cancer types.

The journal’s audience includes clinicians, researchers, and medical oncologists interested in basic, clinical, and translational research. OncoTargets and Therapy aims to share novel insights into new and existing therapies and aid informed acceptance by clinicians and treatment adherence by patients.

All submissions received by the journal will be subject to single-anonymous peer review.

All meta-analyses require a pre-submission check prior to submitting to OncoTargets and Therapy. OncoTargets and Therapy will only accept meta-analyses for epidemiological or clinical submissions. Please complete the pre-submission check form here.

The journal has a special interest in:

• Clinical trial research
• Novel therapeutic targets and innovative agents
• Novel therapeutic regimens for improved benefit and/or decreased side effects
• Development of novel diagnostic and/or prognostic systems

Further considerations when submitting to OncoTargets and Therapy: 

• Studies containing in vivo animal model data will be considered favorably.
• Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. Microarray analyses must be supported by clinical and/or biological data.
• Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
• Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
• Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
• Single nucleotide polymorphism (SNP) studies will not be considered.

Case reports will be considered if clinically focused and make a valuable contribution to the literature.
Study Protocols will be considered if focused on molecular pathology and make a valuable and original contribution to the literature.

Updated 17 October 2025